PPAR-gamma and Nrf2 Agonist Compositions for Gulf War Illness
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Gulf War Illness (GWI) are ineffective in managing neurocognitive impairments and neurodegenerations associated with the condition, as they do not address the specific toxicant exposure-induced brain effects without local necrosis or cell death.
Innovation Solution
Administering a therapeutically effective amount of a nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a nuclear factor erythroid 2-related factor 2 (Nrf2) agonist to ameliorate symptoms and inhibit neurodegeneration, as evidenced by improved behavioral performance and reduced neuropathology in animal models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for Gulf War Illness, then general symptoms may be managed, but neurocognitive impairments and neurodegeneration are not effectively treated
Solution Approach 1:
The patent changes the biochemical parameters of treatment by introducing specific nuclear receptor agonists (PPAR-γ and Nrf2) that target the molecular pathways affected by toxicant exposure. This shifts the treatment approach from symptomatic management to mechanism-based therapy that addresses the root cause of neurocognitive impairments and neurodegeneration associated with Gulf War Illness
Solution Approach 2:
The patent uses nuclear receptor agonists as intermediary substances that mediate between the toxicant-induced cellular damage and the therapeutic response. These agonists act as mediators that activate protective cellular pathways, thereby bridging the gap between the underlying pathology and clinical symptom management
2Reliability
If PPAR-γ and Nrf2 agonists are administered, then neuroprotection and symptom reduction are achieved, but treatment complexity increases
Solution Approach 1:
The patent combines two nuclear receptor agonists (PPAR-γ and Nrf2) into a single therapeutic regimen that targets multiple protective pathways simultaneously. This merging approach achieves synergistic neuroprotection while consolidating what could have been separate treatments into one coordinated therapy, thereby managing complexity through integration rather than multiplication
Data Source
AI summary
The disclosure relates to compositions and methods of treating Gulf War illness or syndrome in a subject. The method comprises administering to a subject in need of treatment an effective amount of a nuclear receptor peroxisome proliferator-activated receptor gamma agonist and a nuclear factor erythroid 2-related factor 2 agonist.